ArticleEClinicalMedicine2026
Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Therapeutics Beyond Delivery: Repurposed Drugs and Biologic Pathways.Current hypertension reports · 2026Review
- Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma.Redox biology · 2026Article
- Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.Journal of the American Society of Nephrology : JASN · 2026Review
- Phase I trial combining sulfasalazine and gamma knife radiosurgery for recurrent glioblastoma.MethodsX · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preeclampsia is a hypertensive pregnancy disorder marked by systemic inflammation and endothelial dysfunction. Sulfasalazine, an anti-inflammatory agent, may have therapeutic potential in preeclampsia. This study investigated its pharmacokinetics, placental transfer, and safety profile of sulfasalazine and its metabolite, sulfapyridine in women with preterm preeclampsia. Methods: A prospective, open-label pharmacokinetic trial was conducted at two hospitals in Melbourne, Australia, (February 2018-December 2020). Participants between 24+0- and 36+0- weeks' gestation with a singleton, non-anomalous pregnancies and a diagnosis of preeclampsia were included received 3 g/day of oral sulfasalazine. Serial maternal blood samples were collected post-dose. Maternal and umbilical cord blood and placental tissue were collected at birth. Primary outcomes were maternal-fetal safety and pharmacokinetics. Maternal plasma levels of soluble fml-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured. All participants receiving at least one dose were included in analyses. The trial was prospectively registered with ANZCTR (12617000226303). Findings: Twelve participants were enrolled, seven had pharmacokinetic sampling. No serious adverse events occurred relating to sulfasalazine use. Sulfasalazine and its metabolite sulfapyridine were detected in maternal plasma, placenta and in the fetal circulation. Maternal-to-fetal transfer of both compounds was confirmed, with some participants showing higher concentrations in cord blood than maternal blood, suggesting potential active or saturable transport mechanisms. Antiangiogenic biomarkers, including sFlt-1, increased post-treatment in most participants. Interpretation: Sulfasalazine was well tolerated in women with preterm preeclampsia and showed maternal and fetal exposure. Placental transfer was evident. These findings support the feasibility of sulfasalazine use in this population and warrant further investigation in a larger clinical trial to evaluate efficacy. Funding: Norman Beischer Medical Research Foundation, University of Melbourne, and NHMRC. Funders had no role in study conduct or manuscript preparation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.